Amgen 3Q Revenues: $5.8 billion (-1%) 3Q Earnings: $2.0 billion (flat) YTD Revenues: $17.0 billion (flat) YTD Earnings: $6.2 billion (+8%) Comments: Enbrel sales were $1.4 billion in the quarter, down 6% due to lower unit demand. Neulasta sales decreased 6% to $1.1 billion due to lower unit demand. Aranesp sales were down 3% to $516 million driven by unfavorable changes in foreign exchange rates and lower unit demand. Prolia sales were $464 million, up 22% driven primarily by higher unit de...